Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI

This article was originally published in The Tan Sheet

Executive Summary

Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.

You may also be interested in...



Perrigo Nutritional Portfolio Grows As Supplement Business Sale Proceeds

Perrigo launches the first generic of Abbott's Ensure Glucerna nutritional shake. The launch could be seen as another potential jolt to lift Perrigo's share price out of a year-long fall that began when Mylan opened its unsuccessful hostile takeover.

Mylan Stretches Games Clock, Adds To Costs For Perrigo Takeover Play

Perrigo says Mylan shows “desperation” in targeting approval by 50% of its shareholders rather than the 80% approval it initially stated in its regulatory filing. A 50% threshold means Mylan would pay more in interest to lenders because it would be required to continue its takeover attempt longer than initially planned.

Mylan Stretches Games Clock, Adds To Costs For Perrigo Takeover Play

Perrigo says Mylan shows “desperation” in targeting approval by 50% of its shareholders rather than the 80% approval it initially stated in its regulatory filing. A 50% threshold means Mylan would pay more in interest to lenders because it would be required to continue its takeover attempt longer than initially planned.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel